Active Not Recruiting PHASE1 INTERVENTIONAL 1-arm NCT05462717

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Sponsor: Revolution Medicines, Inc.

Conditions Advanced Solid Tumor Colorectal Cancer (CRC) Non-Small Cell Lung Cancer (NSCLC) Pancreatic Ductal Adenocarcinoma

Interventions RMC-6291

Updated 17 times since 2022 Last updated: Nov 5, 2024 Started: Sep 19, 2022 Primary completion: Nov 30, 2024 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05462717, this PHASE1 trial focuses on Advanced Solid Tumor and Colorectal Cancer (CRC) and remains ongoing. Sponsored by Revolution Medicines, Inc., it has been updated 17 times since 2022, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

17 versions recorded

Dec 2025 — Present [monthly]

Active Not Recruiting PHASE1
Sep 2025 — Dec 2025 [monthly]

Active Not Recruiting PHASE1
Dec 2024 — Sep 2025 [monthly]

Active Not Recruiting PHASE1
Sep 2024 — Dec 2024 [monthly]

Active Not Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting

▶ Show 12 earlier versions

May 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Mar 2024 — May 2024 [monthly]

Recruiting PHASE1
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE1
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE1
Nov 2023 — Jan 2024 [monthly]

Recruiting PHASE1
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE1
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE1
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE1
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE1
Mar 2023 — Jul 2023 [monthly]

Recruiting PHASE1
Feb 2023 — Mar 2023 [monthly]

Recruiting PHASE1
Sep 2022 — Feb 2023 [monthly]

Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Revolution Medicines, Inc.

Data source: Revolution Medicines, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Angers, France , Bangkok Noi, Thailand , Barcelona, Spain , Belgrade, Serbia , Bethesda, United States , Bordeaux, France , Boston, United States , Buffalo, United States , Chiang Mai, Thailand , Clermont-Ferrand, France and 45 more locations